Hidradenitis Suppurativa

In this segment of Porter’s interview, she delves further into the phase 2 findings on lutikizumab and discusses any adverse events and future research.

In this interview, Porter describes some new and encouraging phase 2 data on lutikizumab treatment for patients with HS who had failed anti-TNF therapy.

The factors highlighted in this analysis may help dermatologists to better understand the concerns, misconceptions, and perceived risks reported by patients with HS.

The THESEUS study was conducted to look at current HS management and the influences on treatment decisions, with the goal of informing future randomized controlled trials.

In this analysis, the investigators note that the clinical association may be helpful to be taken into account as clinicians treat patients with HS.

These phase 2 data on hidradenitis suppurativa patients highlight new information on the use of lutikizumab as a treatment alternative.

Twice-daily PDE4-inhibition using 10–40 mg of orismilast showed promise though further studies may be necessary to validate these findings.